| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2001PNAS...9814583O |
| P356 | DOI | 10.1073/PNAS.251543298 |
| P932 | PMC publication ID | 64725 |
| P698 | PubMed publication ID | 11717412 |
| P5875 | ResearchGate publication ID | 11638790 |
| P2093 | author name string | D Riendeau | |
| M D Percival | |||
| M Ouellet | |||
| P2860 | cites work | COX-2 inhibitors | Q77937806 |
| Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis | Q24646764 | ||
| The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase | Q27729459 | ||
| Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans | Q28174827 | ||
| Aspirin: new cardiovascular uses for an old drug | Q28175524 | ||
| Prostaglandin H synthase-2 inhibitors interfere with prostaglandin H synthase-1 inhibition by nonsteroidal anti-inflammatory drugs | Q28175568 | ||
| The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen | Q28279025 | ||
| 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2 | Q28373083 | ||
| Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs | Q28645859 | ||
| Cyclooxygenases: structural, cellular, and molecular biology | Q29616510 | ||
| Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. | Q31842803 | ||
| Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition | Q33706082 | ||
| Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin | Q34259403 | ||
| The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein | Q34481430 | ||
| Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 | Q34803113 | ||
| Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase | Q35901401 | ||
| Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects | Q36984424 | ||
| Inhibition of platelet prostaglandin synthetase by oral aspirin | Q37050575 | ||
| Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs | Q37464266 | ||
| Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model | Q39440579 | ||
| Purification and characterization of the human recombinant histidine-tagged prostaglandin endoperoxide H synthases-1 and -2. | Q40899068 | ||
| Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. | Q41461839 | ||
| Kinetic basis for selective inhibition of cyclo-oxygenases | Q41817795 | ||
| Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms | Q42063498 | ||
| PGHS-2 inhibitors, NS-398 and DuP-697, attenuate the inhibition of PGHS-1 by aspirin and indomethacin without altering its activity | Q42477234 | ||
| Prostaglandin G2 levels during reaction of prostaglandin H synthase with arachidonic acid | Q44413361 | ||
| A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers | Q45302240 | ||
| Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. | Q53342780 | ||
| Interaction of non-steroidal anti-inflammatory drugs on platelet cyclo-oxygenase and lipoxygenase activity | Q58412200 | ||
| Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity | Q58412235 | ||
| Relationships between thromboxane production, platelet aggregability, and serum concentrations of ibuprofen or flurbiprofen | Q68986592 | ||
| Cumulative antiplatelet effect of low-dose enteric coated aspirin | Q69958726 | ||
| Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents | Q69964826 | ||
| Comparative effect of ibuprofen on endothelial and platelet prostaglandin synthesis | Q70183157 | ||
| Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase | Q70503319 | ||
| Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects | Q71172266 | ||
| Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases | Q72897280 | ||
| My doctor recently recommended that I take low-dose aspirin to minimize the risk of a heart attack or stroke. I routinely take ibuprofen for arthritis pain. Do I need both, and is it safe to combine the two? | Q73043170 | ||
| Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial | Q73423989 | ||
| Fluorescence quenching analysis of the association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic basis of cyclooxygenase-2 selectivity | Q73815277 | ||
| Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans | Q73945571 | ||
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspirin | Q18216 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 14583-14588 | |
| P577 | publication date | 2001-11-20 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin | |
| P478 | volume | 98 |
| Q30977313 | A computer simulation of progesterone and Cox2 inhibitor treatment for preterm labor |
| Q30234292 | Alleviating Promotion of Inflammation and Cancer Induced by Nonsteroidal Anti-Inflammatory Drugs |
| Q93081014 | Antitussive and Anti-inflammatory Dual-active Agents Developed from Natural Product Lead Compound 1-Methylhydantoin |
| Q28221665 | Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin? |
| Q46061276 | COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. |
| Q28167308 | COX-2 selective inhibitors: a literature review of analgesic efficacy and safety in oral-maxillofacial surgery |
| Q28198746 | Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? |
| Q34582722 | Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison |
| Q47372560 | Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited |
| Q44484802 | Characterization of etoricoxib, a novel, selective COX-2 inhibitor |
| Q34530950 | Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor |
| Q38259405 | Competition between low-dose aspirin and other NSAIDs for COX-1 binding and its clinical consequences for the drugs' antiplatelet effects |
| Q92579864 | Cox-2 inhibitors in mandibular third molar surgery |
| Q28192582 | Coxibs and cardiovascular risk |
| Q27658412 | Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1 |
| Q28195566 | Crossreacting drugs and chemicals |
| Q28212127 | Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly? |
| Q44482222 | Cyclo-oxygenase-2 mediated prostaglandin release regulates blood flow in connective tissue during mechanical loading in humans |
| Q36035412 | Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1. |
| Q34601141 | Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs |
| Q35772541 | Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology |
| Q35100868 | Dual, but not selective, COX-1 and COX-2 inhibitors, attenuate acetic acid-evoked bladder irritation in the anaesthetised female cat. |
| Q44318744 | Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects |
| Q58912958 | Estrategia clínica para la prevención de los efectos adversos sobre el tracto digestivo de los antiinflamatorios no esteroideos |
| Q35016968 | Etoricoxib |
| Q35166773 | Etoricoxib for arthritis and pain management |
| Q34610283 | Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis |
| Q41256836 | Evaluation of effects of various drugs on platelet functions using phorbol 12-myristate 13-acetate-induced megakaryocytic human erythroid leukemia cells |
| Q41882213 | Evaluative comparison of systemic aspirin therapy effects on gingival bleeding in post non-surgical periodontal therapy individuals |
| Q37885723 | Gastrointestinal effects of aspirin |
| Q35860889 | Hypersensitivity to non-steroidal anti-inflammatory drugs in childhood |
| Q39314986 | In Silico Screening of Nonsteroidal Anti-Inflammatory Drugs and Their Combined Action on Prostaglandin H Synthase-1. |
| Q28196511 | Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen? |
| Q35021715 | Mechanistic insights into a classic wonder drug--aspirin |
| Q28168971 | Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers |
| Q39584172 | Nitrooxyacyl derivatives of salicylic acid: aspirin-like molecules that covalently inactivate cyclooxygenase-1. |
| Q57169425 | Non-Steroidal Anti-Inflammatory Drug-Induced Gastro-Duodenal Toxicity |
| Q92983673 | Not all (N)SAID and done: Effects of nonsteroidal anti-inflammatory drugs and paracetamol intake on platelets |
| Q28194034 | On the interaction of specific prostaglandin H synthase-2 inhibitors with prostaglandin H synthase-1 |
| Q35033343 | Pooled analysis of clinical trial data evaluating the safety and effectiveness of diclofenac epolamine topical patch 1.3% for the treatment of acute ankle sprain |
| Q46809106 | Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects |
| Q37893966 | Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors |
| Q28165301 | Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation |
| Q36600810 | Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. |
| Q35195182 | Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects |
| Q40086146 | Roles of NSAIDs and aspirin in bleeding peptic ulcers : NSAIDs, aspirin and peptic ulcers |
| Q30629677 | Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks |
| Q28165707 | Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program |
| Q44627113 | Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk |
| Q33440652 | The Pathway Less Traveled: Moving from Candidate Genes to Candidate Pathways in the Analysis of Genome-Wide Data from Large Scale Pharmacogenetic Association Studies |
| Q35028375 | The second generation of COX-2 inhibitors: what advantages do the newest offer? |
| Q45258982 | Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib |
| Q38249105 | Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes |
| Q37785746 | Using pharmacokinetic principles to optimize pain therapy |
| Q28168735 | Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain |
Search more.